Fig 1: Differentiation of mouse and human DASCs in vitro. (A) Representative bright-field imaging of mouse DASCs in 3D Matrigel culture. Scale bar, 20 µm. (B) Immunofluorescence of 3D Matrigel culture of mouse DASCs with the expression of AT1 cell markers Aqp5 and Pdpn on Day 10. Scale bar, 20 µm. (C) Immunostaining on paraffin-embedded sections of ALI differentiation cultures of human DASCs with indicated markers on Day 16. Scale bars, 20 µm. (D) Representative bright field and immunostained images of human DASCs in the monolayer differentiation culture on Day 7. HOPX is an AT1 cell marker. Scale bars, 100 µm. (E) Quantification of the HOPX+ cell frequency of differentiated DASCs isolated from COPD patients with different COPD severity (GOLD) status. Horizontal lines represent the mean within groups, with standard deviation error bars
Fig 2: Expansion of hDASCs under the pharmaceutical-grade condition. (a) Clonogenic cells immunostained with hDASC markers KRT5 and P63 among P4 to P7. Scale bar, 100 µm. (b) Clonogenic cells immunostained with proliferative markers KI67 among P4 to P7. Scale bar, 100 µm. (c, d) Immunostaining of indicated AEC1 markers AQP5 and HOPX on monolayer-differentiated DASCs. Scale bar, 100 µm.
Supplier Page from Abcam for Anti-HOPX/HOD antibody